This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
ANIK or ALKS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ANIK vs. ALKS: Which Stock Is the Better Value Option?
Anika Therapeutics (ANIK) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Anika (ANIK) delivered earnings and revenue surprises of 142.86% and 83.37%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Anika Therapeutics (ANIK) Q2 Earnings Expected to Decline
by Zacks Equity Research
Anika (ANIK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Anika Therapeutics (ANIK) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Anika (ANIK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Anika (ANIK) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Anika (ANIK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Anika Therapeutics (ANIK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Anika (ANIK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ANIK vs. ALKS: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ANIK vs. ALKS: Which Stock Is the Better Value Option?
New Strong Sell Stocks for February 27th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.
Sarepta (SRPT) Looks Good: Stock Adds 7.5% in Session
by Zacks Equity Research
Sarepta (SRPT) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Bausch's (BHC) Arazlo Gets FDA Approval for Acne Vulgaris
by Zacks Equity Research
Bausch (BHC) gets FDA approval for Arazlo Lotion for the topical treatment of acne vulgaris in patients nine years of age or older.
Seattle Genetics Gets Speedy FDA Nod for Bladder Cancer Drug
by Zacks Equity Research
The FDA grants accelerated nod to Seattle Genetics' (SGEN) Padcev to treat urothelial cancer. It also assigns Breakthrough Therapy tag to tucatinib for advanced/metastatic HER2-positive breast cancer.
Epizyme Stock Up on Positive Advisory Votes for Tazemetostat
by Zacks Equity Research
Epizyme (EPZM) gets favorable votes from the FDA's ODAC for tazemetostat in patients with metastatic or locally advanced epithelioid sarcoma not eligible for curative surgery.
Biotech Stock Outlook: M&A Activity Retains Growth Streak
by Ekta Bagri
The biotech sector enjoys a good run in 2019 on the back of the M&A activities and positive pipeline updates underway. We expect this momentum to stay in 2020 as well.
Mallinckrodt Initiates Phase IV Study on Acthar for Keratitis
by Zacks Equity Research
Mallinckrodt (MNK) initiates phase IV, multi-center, multiple-dose, open-label study to assess the effects of lead drug Acthar Gel as a therapy option in patients with severe keratitis.
Pacira's Exparel Spurs Growth, Exclusive Reliance a Concern
by Zacks Equity Research
Pacira (PCRX) focuses on improving sales of its flagship product Exparel. The drug's label expansion programs also look encouraging. However, sole dependence on the drug is a constant worry.
Horizon Therapeutics Eye Drug Gets Positive FDA Advisory Vote
by Zacks Equity Research
Horizon Therapeutics' (HZNP) pipeline candidate, teprotumumab, gets favorable vote from DODAC of the FDA for the treatment of Thyroid Eye Disease.
bluebird (BLUE) Catches Eye: Stock Jumps 6.8%
by Zacks Equity Research
bluebird (BLUE) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Biogen's Gosuranemab Fails in Phase II Brain Disorder Study
by Zacks Equity Research
Biogen's (BIIB) gosuranemab fails to meet primary endpoint in a phase II study evaluating gosuranemab (BIIB092) in patients with progressive supranuclear palsy, a degenerative brain disorder.
Blueprint Medicines (BPMC) Up More Than 30% YTD: Here's Why
by Zacks Equity Research
Blueprint Medicines' (BPMC) NDA for avapritinib to treat PDGFRA Exon 18 mutant gastrointestinal stromal tumors (GIST) and fourth-line GIST is under FDA review. Other pipeline candidates also advance.
ProQR (PRQR) Begins Dosing in Phase I/II Eye Disorder Study
by Zacks Equity Research
ProQR (PRQR) doses the first patient in the phase I/II Aurora study on QR-1123, which is being evaluated for treating patients with autosomal dominant retinitis pigmentosa.
BioCryst Submits NDA for Hereditary Angioedema Candidate
by Zacks Equity Research
BioCryst (BCRX) files a new drug application to the FDA for once-daily berotralstat (BCX7353), which is being developed for the prevention of hereditary angioedema attacks.
Amgen's Osteoporosis Drug Evenity Gets Approval in Europe
by Zacks Equity Research
The EC grants marketing authorization to Amgen (AMGN) and partner UCB's Evenity for the treatment of severe osteoporosis in postmenopausal women at high risk of fracture.
Vertex's Kalydeco Gets EU Approval to Treat CF in Infants
by Zacks Equity Research
Vertex's (VRTX) Kalydeco gains EU nod for use in infants with cystic fibrosis aged from six to less than 12 months with at least one of specified nine mutations in the CFTR gene.
VistaGen Up on Fast Track Designation for Anxiety Disorder Drug
by Zacks Equity Research
The FDA assigns a Fast Track status to VistaGen's (VTGN) neuroactive nasal spray PH94B for the on-demand treatment of social anxiety disorder. Stock surges.
Intra-Cellular Therapies (ITCI) in Focus: Stock Moves 6.1% Higher
by Zacks Equity Research
Intra-Cellular Therapies (ITCI) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.